Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Debt Repayments (2016 - 2024)

Ironwood Pharmaceuticals (IRWD) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $15.0 million as the latest value for Q4 2024.

  • Quarterly Long-Term Debt Repayments fell 40.0% to $15.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $65.0 million through Dec 2024, down 32.24% year-over-year, with the annual reading at $65.0 million for FY2024, 35.0% down from the prior year.
  • Long-Term Debt Repayments hit $15.0 million in Q4 2024 for Ironwood Pharmaceuticals, down from $25.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $25.0 million in Q4 2023 to a low of $15.0 million in Q4 2024.